Abbisko Cayman Limited (2256) AI Stock Analysis

• Market Cap: HK$9.20B
• Dividend Yield: N/A
• Average Volume (3M): 4.32M
• Price to Earnings (P/E): 47.3
• Beta (1Y): 1.45
• Revenue Growth: 23.37%
• EPS Growth: N/A
• Country: HK
• Employees: 281
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.56
• Shares Outstanding: 680,105,350
• 10 Day Avg. Volume: 4,319,715
• 30 Day Avg. Volume: 4,318,146
• PEG Ratio: -1.02
• Price to Book (P/B): 1.56
• Price to Sales (P/S): 6.07
• P/FCF Ratio: -150.44
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: HK$24.45
• Price Target Upside: 80.71% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 57 Neutral
• Price Target: HK$15.00 ▲(10.86% Upside)

Abbisko Cayman Limited's overall stock score is primarily influenced by its financial performance, which shows promising revenue growth and improved net income. However, technical indicators suggest bearish momentum, and the stock's high P/E ratio indicates potential overvaluation. The absence of a dividend yield further impacts its valuation negatively.

Positive Factors

Revenue Growth

The company's strong revenue growth indicates a successful execution of its business model, enhancing its market position and potential for future profitability.

Balance Sheet Health

A strong balance sheet with low debt enhances financial stability, providing flexibility for strategic investments and weathering economic fluctuations.

Cash Flow Improvement

Improved free cash flow indicates better cash management, which is crucial for funding operations and future growth without relying heavily on external financing.

Negative Factors

Negative Operating Cash Flow

Negative operating cash flow suggests challenges in generating cash from core operations, which could impact the company's ability to sustain growth and meet financial obligations.

Profitability Challenges

Ongoing profitability challenges, despite revenue growth, highlight issues in cost management and operational efficiency, potentially hindering long-term financial health.

Low Return on Equity

Low return on equity indicates inefficient use of shareholder funds, which could deter investment and affect the company's ability to raise capital in the future.

Abbisko Cayman Limited Business Overview & Revenue Model

Company Description

Abbisko Cayman Limited (2256) is a biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of cancer and other diseases. The company operates primarily in the biotechnology sector, leveraging cutting-edge research and development to create novel drug candidates targeting unmet medical needs. Abbisko's core products include drug candidates in various stages of clinical trials, emphasizing precision medicine and personalized therapeutic approaches.

How the Company Makes Money

Abbisko Cayman Limited generates revenue through a multi-faceted approach that includes the development and commercialization of its proprietary drug candidates. The company's primary revenue streams consist of milestone payments from pharmaceutical partnerships, licensing agreements for drug candidates, and potential royalties from sales of products developed in collaboration with other biotech firms or pharmaceutical companies. Significant partnerships with larger pharmaceutical companies enhance Abbisko's financial stability by providing upfront payments and shared development costs, which contribute to its earnings as they progress through clinical trials and regulatory approvals.

Abbisko Cayman Limited Financial Statement Overview

Summary

Abbisko Cayman Limited has shown significant revenue growth and improved net income in the latest year, indicating potential for future profitability. The balance sheet is strong with low debt and high equity, but the company must continue to manage its cash flows effectively to ensure long-term sustainability. The recent improvements in financial performance are promising, but sustained effort is required to maintain and build upon this progress.

Income Statement

Abbisko Cayman Limited has shown a substantial increase in revenue in 2024 compared to 2023. The gross profit margin is 100% for both years, indicating all revenue contributes directly to profit before expenses. However, despite revenue growth, the company has struggled with profitability, as reflected by negative EBIT and EBITDA margins in recent years, although net income turned positive in 2024, indicating some improvement.

Balance Sheet

The company maintains a strong equity position with a very low debt-to-equity ratio, indicating limited reliance on debt financing. The equity ratio is high, suggesting strong financial stability. However, the return on equity is low due to prior years of negative net income, although there was a positive turn in 2024 which indicates some improvement in leveraging equity for profits.

Cash Flow

Operating cash flow remains negative, indicating that the business is not generating sufficient cash from operations. However, free cash flow has improved in 2024 compared to 2023, suggesting better cash management. The company has also reduced its capital expenditures, which might have helped in improving free cash flow.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	618.84M	503.99M	19.06M	0.00	22.68M	0.00
Gross Profit	618.84M	503.99M	19.06M	0.00	22.68M	0.00
EBITDA	96.28M	-15.28M	-410.99M	-492.62M	-1.80B	-150.21M
Net Income	149.98M	28.30M	-431.58M	-498.29M	-1.81B	-706.81M
Balance Sheet
Total Assets	2.44B	2.11B	2.12B	2.49B	2.65B	665.97M
Cash, Cash Equivalents and Short-Term Investments	2.38B	2.01B	1.96B	2.35B	2.57B	636.66M
Total Debt	17.77M	24.29M	35.72M	45.58M	53.80M	4.31M
Total Liabilities	217.96M	148.71M	134.28M	143.16M	118.48M	1.77B
Stockholders Equity	2.22B	1.96B	1.98B	2.35B	2.54B	-1.10B
Cash Flow
Free Cash Flow	126.03M	-20.32M	-456.98M	-366.64M	-182.08M	-121.60M
Operating Cash Flow	129.00M	-12.92M	-444.73M	-343.90M	-169.74M	-117.56M
Investing Cash Flow	239.41M	-196.50M	378.52M	-216.57M	-1.46B	-11.25M
Financing Cash Flow	23.09M	-80.86M	-16.11M	-20.81M	2.10B	505.89M

Abbisko Cayman Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 13.53
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2256, the sentiment is Negative. The current price of 13.53 is below the 20-day moving average (MA) of 14.01, below the 50-day MA of 14.59, and above the 200-day MA of 12.02, indicating a neutral trend. The MACD of -0.30 indicates Positive momentum. The RSI at 39.53 is Neutral, neither overbought nor oversold. The STOCH value of 21.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2256.

Abbisko Cayman Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
2256	57 Neutral	HK$9.20B	47.27	6.73%	―	23.37%	―
1672	54 Neutral	HK$13.12B	-44.32	-12.74%	―	-76.58%	-4.90%
9966	53 Neutral	HK$9.97B	40.68	13.34%	―	206.58%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
2142	51 Neutral	HK$11.34B	16.93	35.80%	―	59.70%	239.97%
2616	42 Neutral	HK$8.17B	-18.58	-95.84%	―	-55.64%	-158.67%

Abbisko Cayman Limited Corporate Events

Abbisko Therapeutics Secures FDA Clearance for Pioneering Cancer Drug

Abbisko Cayman Limited announced that its subsidiary, Abbisko Therapeutics, has received clearance from the U.S. FDA for its Investigational New Drug application for ABSK141, a novel oral small-molecule KRAS G12D inhibitor. This development marks a significant step in addressing the challenging KRAS G12D mutation found in various solid tumors, including pancreatic, colorectal, and non-small cell lung cancers. The IND clearance allows Abbisko to proceed with Phase I/II clinical trials to evaluate the drug’s safety and efficacy, potentially strengthening its position in the oncology pharmaceutical industry.

Abbisko Therapeutics Showcases Promising Phase III Results for TGCT Treatment

Abbisko Therapeutics, a subsidiary of Abbisko Cayman Limited, presented promising long-term efficacy and safety results from its Phase III MANEUVER study of pimicotinib at the CTOS 2025 Annual Meeting. The study demonstrated significant improvements in tumor response and patient quality of life, reinforcing pimicotinib’s potential for long-term use in TGCT patients. The results highlight the drug’s robust and durable response, with a notable increase in objective response rate and quality of life improvements over time, positioning Abbisko as a key player in the TGCT treatment landscape.

Abbisko Therapeutics Advances Phase II Study for NSCLC Treatment

Abbisko Cayman Limited announced that its subsidiary, Abbisko Therapeutics, has completed the first patient dosing in a Phase II clinical study of ABSK043, an oral small-molecule PD-L1 inhibitor, in combination with Glecirasib for treating non-small cell lung cancer (NSCLC) with KRAS G12C mutation. This milestone marks a significant advancement in the development of this treatment regimen, which aims to address a prevalent oncogenic driver in human cancer. The study, approved by China’s National Medical Products Administration, seeks to evaluate the safety and efficacy of this novel combination therapy, potentially impacting the company’s market positioning and offering new hope for patients with advanced NSCLC.

Abbisko Therapeutics Unveils Promising Preclinical Cancer Drug Findings

Abbisko Therapeutics announced promising preclinical findings for two of its drug candidates, the CDK4/2 inhibitor ABK-CDK-1 and the SMARCA2 PROTAC degrader ABK-SM2-1, at the 37th AACR-NCI-EORTC Conference. These developments highlight the company’s efforts to overcome limitations of existing cancer treatments, potentially enhancing its positioning in the oncology sector and offering new therapeutic options for patients.

Abbisko’s Pimicotinib Shows Promising Results in Phase III TGCT Trial

Abbisko Cayman Limited announced promising longer-term efficacy and safety outcomes from its Phase III MANEUVER trial of pimicotinib, a CSF-1R inhibitor, for treating tenosynovial giant cell tumour (TGCT). Presented at ESMO 2025, the results showed significant and durable tumor response improvements, with a favorable safety profile, suggesting pimicotinib’s potential as a leading therapy in TGCT management. These findings enhance the drug’s commercial prospects and Abbisko’s position in the oncology market.

Abbisko Cayman Limited Grants Share Options to Directors and Employees

Abbisko Cayman Limited has announced the grant of 6,343,508 share options to three directors and certain employees under its Post-IPO Share Option Scheme. The options are subject to performance targets at both group and individual levels, with vesting scheduled over four years. This move aims to align the interests of the company’s leadership and employees with its strategic goals, potentially enhancing its competitive positioning in the pharmaceutical industry.